Novozymes enters into an exclusive supplier agreement to supply Recombumin for Type 2 Diabetes drug

NOTTINGHAM, UK – September 30, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has concluded an exclusive supply agreement with ConjuChem LLC of Los Angeles, California. Novozymes will supply its recombinant human albumin, Recombumin, for use in the development of a new GLP-1 analog in Phase 2 testing for Type 2 diabetes. The use of Recombumin in the development of the product potentially significantly reduces dosing frequency, allowing patients to self-inject once per week instead of once or twice daily.

“This supply agreement is a great example of using Novozymes’ Recombumin as a vehicle for extending the half-life of peptides in drug delivery applications,” said Thomas Videbæk, Executive Vice President of Novozymes’ BioBusiness. “Also the agreement for this new drug will potentially pave the way for the use of Recombumin in other peptide-based therapies.”

EXCO INTOUCH SECURES GROWTH INVESTMENT FROM SEP

Mobile patient communication leader to use funds to accelerate growth strategy

LONDON, UK - 29 September, 2011 - Leading growth equity and venture capital group Scottish Equity Partners (SEP) has led an initial £3m pound investment in Exco InTouch, the leading provider of mobile patient communication and management solutions for the pharmaceutical and healthcare sector.

SEP has taken a minority stake in the company which will use the funds to accelerate its expansion, enabling it to take advantage of significant growth opportunities in the clinical technology sector, particularly in the emerging mobile patient communication market.

Thermo Fisher Scientific Launches New Total Nitrogen and Sulfur Analyzer for Precise and Accurate Analysis of Petroleum Products Using a Single Introduction Module

CAMBRIDGE, UK (September 27, 2011) - Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new Total Nitrogen and Total Sulfur (TN/TS) analyzer, which features an innovative direct injection design providing the capacity to analyze both heavy and light hydrocarbons without changing introduction modules. As a result of the versatility, precision and accuracy offered by the Thermo Scientific iPRO 5000 series analyzer, scientists in petrochemical and commercial testing laboratories, oil refineries, R&D centers and chemical plants, will benefit from significant time savings and productivity advantages, in addition to total ASTM compliance.

Thermo Fisher Scientific Introduces New Imaging ATR Accessory for Fast and Reliable FT-IR Chemical Imaging Analyses

MADISON, Wis.,(Sep 23, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of a new imaging attenuated total reflectance (ATR) accessory offering enhanced spatial resolution and high speed data acquisition capabilities for Fourier transform infrared (FT-IR) chemical imaging applications. The Thermo Scientific imaging ATR accessory has been designed to seamlessly and effortlessly integrate with the Thermo Scientific range of FT-IR microscopes to enable efficient, fast and reliable chemical imaging of challenging samples. This is of particular benefit to manufacturers of composite structures, paper products, pharmaceutical dosage forms, biological tissues, polymer films and coatings. The product was showcased at the JAIMA Expo 2011 in Makuhrai Messe, Japan.

ATR is a popular sampling technique for infrared spectroscopy allowing direct contact sampling of solids and liquids without further preparation. When coupled with an FT-IR microscope, ATR provides a unique capability for exploring the microscopic structure of heterogeneous samples. Single point ATR mapping, while more flexible in terms of total image size and dimensions, requires many separate contact points to build up the imaging data set. The Thermo Scientific imaging ATR accessory provides a more rapid method because it requires the sample to be compressed only once against an extended area of contact. Data collection may then proceed at the same speed as normal transmission or external reflectance experiments.

The new imaging ATR accessory greatly simplifies the task of obtaining high quality infrared spectra in cases of samples that are difficult to prepare for transmission analysis. Observable features in specimens, such as defects, particles, fibers or inks, may be effectively analyzed with spatial resolution improved by a factor of four relative to transmission measurements. The accessory quickly snaps into the sample holder feature of Thermo Scientific Nicolet iN10, Nicolet iN10 MX and Nicolet Continuµm microscopes in a matter of seconds without the need of tools. All standard microscope optics remain available, thus avoiding any concerns of alignment or down time when switching between sampling modes. Transmission, external reflection, micro-ATR and imaging-ATR capabilities are all immediately available to address the requirements of any FT-IR microscopy application.

For more information about the new Thermo Scientific imaging ATR accessory, please call 800-532-4752, e-mail analyze@thermofisher.com or visit www.thermoscientific.com/ftir.

###

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly $11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit www.thermofisher.com.

For further press information please contact: Laura Browne, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom Tel: + 44 1477 539539 Fax: +44 1477 539 540 E-mail: thermo@scottpr.com

###

Leicester’s Hospitals and Synergy Health raise decontamination standards through new facility

Swindon, UK (15th September 2011) –University Hospitals of Leicester NHS Trust and Synergy Health (UK) Limited, the leading provider of specialist outsourced services to healthcare providers, have officially launched a multi-million pound 'super-centre' for decontaminating surgical instruments today.

The facility, formally opened by NHS Medical Director Professor Sir Bruce Keogh at Meridian Business Park, Leicester, will enable the Trust to streamline this critical sterile service, further enhance the quality of sterile instrument output and benefit from new revenue streams.

Thermo Fisher Scientific Launches iTEVA Precision Software for Rapid Analysis of Precious Metals and High Concentration Elements

CAMBRIDGE, UK (September 15, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new software module to enable high-precision and automated analysis of precious metals and high concentration elements. The Thermo Scientific iTEVA Precision software seamlessly integrates with the Thermo Scientific iCAP 6000 Series of inductively coupled plasma optical emission spectrometers (ICP-OES) to deliver analytical results with high precision. Designed specifically for the metallurgy industry, the new module enhances the Thermo Scientific iTEVA software solution and delivers a simple and efficient workflow for high-precision analysis with real-time data processing using the bracketing standards approach.

Greenphire Closes Series A Financing Led by FirstMark Capital

KING OF PRUSSIA, PA (September 14, 2011) – Greenphire, the leading provider of web-based payment and communication technologies for the healthcare clinical trials industry, announced today that it has completed a Series A financing led by prominent New York-based venture capital firm, FirstMark Capital.

All of Greenphire’s existing angel investors, including leading healthcare industry veterans and entrepreneurs, participated in the funding.  Gerald A.Poch, a Founder and Managing Director at FirstMark Capital, will join Greenphire’s Board of Directors alongside the company’s existing Directors—CEO Samuel Whitaker, Dr. Neil Rotherham, and David Reuter—as part of the financing.  The Series A funding will support the recent launch of Greenphire’s innovative eClinicalGPS technology, a clinical payment platform designed to automate site and vendor payments within the clinical research environment.  Additionally, the capital will be used to expand global sales and marketing initiatives for Greenphire’s flagship technology platform, the ClinCard System, which currently hosts a client base of more than 140 clinical trials sponsors, research sites, contract research organizations and research universities.